Cargando…

Coagulation abnormalities and thrombosis in patients with COVID-19

Detalles Bibliográficos
Autores principales:	Levi, Marcel, Thachil, Jecko, Iba, Toshiaki, Levy, Jerrold H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213964/ https://www.ncbi.nlm.nih.gov/pubmed/32407672 http://dx.doi.org/10.1016/S2352-3026(20)30145-9

Ejemplares similares

Proposal of the Definition for COVID-19-Associated Coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2021)

Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)

The unique characteristics of COVID-19 coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2020)

Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines
por: Iba, Toshiaki, et al.
Publicado: (2022)

Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic
por: Iba, Toshiaki, et al.
Publicado: (2021)

Abnormal coagulation tests before kidney biopsies—what next?
por: Thachil, Jecko
Publicado: (2013)

Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination()()
por: Iba, Toshiaki, et al.
Publicado: (2022)

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey
por: Iba, Toshiaki, et al.
Publicado: (2017)

COVID-19 coagulopathy: is it disseminated intravascular coagulation?
por: Levi, Marcel, et al.
Publicado: (2020)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

DOACs and “newer” hemophilia therapies in COVID‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
por: Thachil, Jecko, et al.
Publicado: (2020)

The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity
por: Iba, Toshiaki, et al.
Publicado: (2016)

Intracellular communication and immunothrombosis in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2022)

Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
por: Iba, Toshiaki, et al.
Publicado: (2019)

The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2023)

Coagulation disorder in COVID-19
por: Kander, Thomas
Publicado: (2020)

Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
por: Iba, Toshiaki, et al.
Publicado: (2022)

The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2023)

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
por: Iba, Toshiaki, et al.
Publicado: (2022)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation
por: Iba, Toshiaki, et al.
Publicado: (2018)

Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation
por: Iba, Toshiaki, et al.
Publicado: (2019)

Lessons learnt from COVID‐19 coagulopathy
por: Thachil, Jecko
Publicado: (2021)

The coagulopathy, endotheliopathy, and vasculitis of COVID-19
por: Iba, Toshiaki, et al.
Publicado: (2020)

Coagulation abnormalities in critically ill patients
por: Levi, Marcel, et al.
Publicado: (2006)

The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro
por: Iba, Toshiaki, et al.
Publicado: (2017)

Vascular mechanisms and manifestations of COVID-19
por: Levi, Marcel, et al.
Publicado: (2021)

Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again
por: Levy, Jerrold H., et al.
Publicado: (2021)

Rotational thromboelastometry in critically ill COVID‐19 patients does not predict thrombosis
por: Dujardin, Romein W. G., et al.
Publicado: (2022)

Exploring the epidemiology of disseminated intravascular coagulation: protocol for the DANish Disseminated Intravascular Coagulation (DANDIC) Cohort Study
por: Flæng, Simon, et al.
Publicado: (2022)

Differentiating biochemical from clinical heparin resistance in COVID-19
por: Lisman, Ton, et al.
Publicado: (2020)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

A proposal for staging COVID‐19 coagulopathy
por: Thachil, Jecko, et al.
Publicado: (2020)

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019)

COVID-19 and its implications for thrombosis and anticoagulation
por: Connors, Jean M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k1gs38261gtesljed0q32i309l